In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Schering-Plough gets second antibody from partner Centocor

Executive Summary

Schering-Plough has exercised its option to license rights to Centocor's human antibody CNTO148 (golimumab). The molecule has completed Phase II testing for rheumatoid arthritis (RA) and will move into Phase III early next year; it is also being developed against other immune-mediated inflammatory diseases.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies